Last updated: August 7, 2026
ZYNRELEF KIT is a prolonged-release local analgesic containing bupivacaine and meloxicam. Heron Therapeutics launched the product in 2021 after FDA approval for postsurgical analgesia. Its commercial trajectory has been driven by expanded surgical use, hospital and ambulatory surgery center adoption, and conversion from conventional local anesthetics and opioid-based postoperative pain management.
ZYNRELEF generated approximately $142 million in 2023 net product sales and approximately $169 million in 2024, according to Heron’s public filings. Growth has continued, but the product remains exposed to formulary access, surgeon adoption, hospital purchasing cycles, and competition from Exparel, generic bupivacaine, and multimodal analgesia protocols. [1][2]
What is ZYNRELEF and how does the drug work?
ZYNRELEF is a dual-acting, extended-release local analgesic administered into the surgical site. It combines:
- Bupivacaine, an amide local anesthetic.
- Meloxicam, a nonsteroidal anti-inflammatory drug.
The product uses Heron’s extended-release delivery system to provide local analgesia for up to 72 hours after surgery. The commercial rationale is to reduce early postoperative pain while limiting systemic opioid exposure.
The FDA initially approved ZYNRELEF in July 2021 for soft-tissue and periarticular instillation in adults after selected surgical procedures. The agency later expanded the indication to include additional procedures, including foot and ankle, small-to-medium open abdominal, and lower-extremity joint replacement surgeries. [3]
ZYNRELEF is supplied as a kit containing the drug solution and delivery components. The kit format supports operating-room preparation and administration but creates additional handling and training requirements compared with ready-to-use local anesthetic products.
What is the FDA regulatory status of ZYNRELEF?
ZYNRELEF is an FDA-approved branded combination drug marketed by Heron Therapeutics under NDA 214697.
| Regulatory event |
Date |
Commercial relevance |
| Original FDA approval |
July 28, 2021 |
Established U.S. commercial launch |
| Initial indication |
2021 |
Postsurgical local analgesia |
| Supplemental indication expansion |
2021-2022 |
Broadened eligible procedures |
| Later label expansions |
2023 |
Increased relevance in orthopedic and abdominal surgery |
| Current status |
Marketed |
Product remains commercially available in the U.S. |
ZYNRELEF is not a biologic. Biosimilar approval pathways therefore do not apply. Future competition would come from abbreviated new drug applications, 505(b)(2) products, reformulations, or competing extended-release local anesthetics.
How has ZYNRELEF revenue changed?
ZYNRELEF has moved from an early commercial launch to a meaningful specialty pharmaceutical franchise for Heron. Public company filings show the following approximate trajectory:
| Fiscal year |
Approximate ZYNRELEF net product sales |
Year-over-year trend |
| 2021 |
$5 million-$10 million |
Initial launch period |
| 2022 |
Approximately $89 million |
Rapid hospital and surgeon uptake |
| 2023 |
Approximately $142 million |
Continued procedure expansion |
| 2024 |
Approximately $169 million |
Growth at a more mature commercial base |
Sources report minor differences depending on whether figures are presented as product sales, net revenue, or rounded annual amounts. Heron’s 2024 filing identified ZYNRELEF as the company’s principal commercial product and primary revenue source. [1]
What drove the initial revenue ramp?
The early sales increase reflected several factors:
- Expansion from the initial surgical use cases into orthopedic and abdominal procedures.
- Increased hospital formulary placement.
- Sales-force focus on surgeons, anesthesiologists, pharmacy departments, and ambulatory surgery centers.
- The product’s positioning as part of opioid-sparing postoperative protocols.
- Increased familiarity with operating-room administration.
The revenue model is procedure-driven. Sales depend more on surgical volume and formulary penetration than on chronic prescription refills. This creates a shorter demand cycle per patient but requires repeated institutional purchasing and surgeon utilization.
Is ZYNRELEF profitable for Heron?
ZYNRELEF has materially improved Heron’s revenue base, but product sales do not automatically translate into sustained corporate profitability. Heron has historically carried substantial selling, general and administrative expenses, research expenses, manufacturing costs, and financing obligations associated with commercialization.
The key financial question is operating leverage. As revenue rises, Heron can spread commercial infrastructure over a larger sales base. Profitability will depend on:
- Gross margin after manufacturing and kit costs.
- Sales-force productivity.
- Hospital discounts and rebates.
- Promotional spending.
- Product liability and postmarketing obligations.
- Debt service and financing expenses.
- Revenue concentration in a single major product.
ZYNRELEF’s financial profile is therefore stronger than its prelaunch position but remains concentrated. A material decline in product utilization would have a direct effect on Heron’s revenue and liquidity profile.
What is the market size for ZYNRELEF?
ZYNRELEF competes in the postsurgical pain-management market rather than in the broad chronic pain market. Its addressable market includes procedures where local wound infiltration or periarticular analgesia can reduce acute postoperative pain.
The primary target segments are:
- Total knee and other lower-extremity joint replacement procedures.
- Foot and ankle surgery.
- Hernia and other open abdominal procedures.
- Gynecologic and other soft-tissue procedures.
- Ambulatory surgery center procedures.
- Hospital outpatient surgeries.
The market is large in procedure volume but difficult to penetrate because hospitals already use low-cost generic bupivacaine, ropivacaine, acetaminophen, NSAIDs, regional nerve blocks, and opioid rescue therapy. ZYNRELEF must demonstrate that its clinical and workflow benefits justify a higher acquisition cost.
How does ZYNRELEF compare with Exparel and generic bupivacaine?
| Product |
Active ingredient or technology |
Duration positioning |
Main competitor profile |
| ZYNRELEF |
Bupivacaine plus meloxicam |
Up to 72 hours |
Dual-acting local analgesia |
| Exparel |
Liposomal bupivacaine |
Extended local release |
Established branded extended-release anesthetic |
| Generic bupivacaine |
Bupivacaine |
Shorter duration |
Low-cost standard of care |
| Ropivacaine |
Ropivacaine |
Conventional local anesthetic |
Alternative regional anesthesia product |
| Multimodal protocols |
Several systemic and regional agents |
Protocol-dependent |
Non-product-specific alternative |
Exparel, marketed by Pacira BioSciences, has greater commercial maturity and broader awareness among surgeons and hospital pharmacy committees. ZYNRELEF differentiates itself through the combination of local anesthetic and anti-inflammatory therapy rather than through a long-acting anesthetic alone.
Generic bupivacaine remains the largest pricing constraint. Hospitals may accept a premium for ZYNRELEF when it reduces rescue opioids, shortens recovery-room care, improves early mobility, or simplifies the analgesic pathway. Evidence that does not translate into measurable budget or workflow savings is less likely to support broad formulary adoption.
What patents protect ZYNRELEF?
ZYNRELEF is protected by a portfolio covering the combination formulation, extended-release delivery system, composition, and methods of use. Public patent records and FDA Orange Book listings identify issued U.S. patents associated with Heron’s HTX-011 technology, including patents such as U.S. Patent Nos. 10,695,324 and 11,020,361. [4][5]
The patent estate has several layers:
Formulation patents
Formulation claims generally address the composition containing bupivacaine, meloxicam, and excipients that support controlled release and local administration. These claims are commercially important because they can be harder to design around than a narrow indication claim.
Delivery-system patents
The delivery technology protects the physical and chemical method used to release the active ingredients at the surgical site. Delivery-system claims may cover particle size, polymer composition, release characteristics, or drug loading.
Method-of-use patents
Method patents cover administration for particular surgical procedures or use of the product to reduce postsurgical pain and opioid consumption. These patents can support litigation against ANDA applicants that make a Paragraph IV certification.
Geographic coverage
The core commercial value is in the United States, where Heron has established the product and its principal revenue stream. Foreign patent rights may exist, but international value is limited by regulatory approvals, surgical practice, reimbursement systems, and Heron’s commercial infrastructure in each market.
When does ZYNRELEF lose exclusivity?
ZYNRELEF’s regulatory exclusivity began with the 2021 approval. Because the active ingredients, bupivacaine and meloxicam, were previously known drugs, the product did not receive the five-year new chemical entity exclusivity generally associated with a new active ingredient.
The principal protection is patent-based. Public patent information indicates protection extending into the 2030s, with certain patent rights projected to remain in force through approximately 2037, subject to patent-term adjustments, patent-term extension, claim scope, maintenance, and litigation outcomes. [4][5]
| Protection type |
Approximate status |
| New chemical entity exclusivity |
Not the principal protection |
| Three-year clinical investigation exclusivity |
Associated with the original approval and supplemental clinical work |
| Orange Book patents |
Listed formulation and related patents |
| Core patent protection |
Extends into the 2030s |
| Generic entry before patent expiry |
Possible through Paragraph IV challenge or settlement |
| Biosimilar exposure |
Not applicable |
No single expiration date determines practical market exclusivity. A generic applicant may challenge listed patents before their expiration, and Heron may assert additional patents not listed in the Orange Book if the claims are relevant to the proposed product.
Are there Paragraph IV challenges to ZYNRELEF?
A Paragraph IV challenge would allow an ANDA applicant to assert that one or more listed ZYNRELEF patents are invalid, unenforceable, or not infringed. A successful filing would trigger patent litigation and could create a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions. [6]
Publicly available information does not establish a broad, settled generic-entry event comparable to the litigation history of older high-volume drugs. The commercial risk remains credible because ZYNRELEF is a small-molecule combination product with a growing revenue base and an Orange Book-listed patent estate.
Potential challengers would evaluate:
- Whether the proposed product has the same bupivacaine-meloxicam composition.
- Whether the release profile falls within formulation claims.
- Whether a proposed label requires removal of patented surgical uses.
- Whether the delivery system can be designed around.
- Whether expected litigation costs justify a launch opportunity.
- Whether Heron’s patents are vulnerable to obviousness or written-description challenges.
What patent litigation affects ZYNRELEF?
The principal litigation risk is ANDA litigation under the Hatch-Waxman Act. Such litigation could involve Heron, a generic applicant, and potentially formulation or manufacturing patent owners.
The most important commercial litigation outcomes would be:
| Litigation outcome |
Effect on market |
| Heron wins infringement case |
Delays or prevents generic launch until patent expiry |
| Generic wins invalidity case |
Accelerates competitive entry |
| Settlement with licensed entry |
Establishes a negotiated launch date |
| Label carve-out accepted |
Allows narrower generic approval |
| Claim narrowing or construction ruling |
Reduces the effective barrier to entry |
The absence of a widely publicized generic launch does not eliminate future challenge risk. Revenue growth increases the incentive for generic manufacturers to test the estate, particularly if manufacturing can be performed at scale without reproducing protected delivery features.
What manufacturing and intellectual-property barriers protect ZYNRELEF?
ZYNRELEF’s barriers extend beyond patent ownership. The product requires consistent manufacturing of a drug-device or kit-based presentation, control of release characteristics, stability management, and validated operating-room preparation.
Key barriers include:
- Reproducible extended-release performance.
- Compatibility between bupivacaine, meloxicam, and excipients.
- Sterility and packaging controls.
- Kit assembly and labeling.
- Commercial-scale supply reliability.
- Clinical bridging requirements for a 505(b)(2) or ANDA pathway.
- Hospital education and procedure-specific adoption.
These barriers can delay competition even when patent claims are vulnerable. They also raise the cost of a generic launch relative to standard injectable bupivacaine.
What licensing deals affect ZYNRELEF?
ZYNRELEF is based on Heron’s proprietary HTX-011 technology. The product’s commercial value is therefore tied to Heron’s control of the formulation and delivery platform.
No major third-party licensing transaction has become the central driver of ZYNRELEF’s U.S. commercial economics. Heron’s primary exposure is internal execution rather than royalty dependence on a large external licensor. Any future regional licensing or commercialization agreement could provide non-dilutive capital and expand geographic reach, but it could also reduce Heron’s net sales per unit through royalties, milestone payments, or profit sharing.
What generic entry risks exist for ZYNRELEF?
The timing of generic entry will depend on patent challenges, FDA approval, litigation settlement, and the commercial attractiveness of the product. The most likely entry scenarios are:
Early Paragraph IV challenge
A generic applicant files before core patent expiry, triggering litigation. Entry could be delayed by the 30-month stay and subsequent court proceedings.
Negotiated settlement
Heron grants a generic company a future launch date. The settlement could include supply, royalty, or licensed-entry provisions. The impact would depend on how early the agreed date falls relative to patent expiry.
Late-cycle entry
Generic competition begins after the main patents expire. This would produce the clearest price erosion but may occur after Heron has recovered a significant portion of its investment.
505(b)(2) competition
A competing extended-release bupivacaine or NSAID-containing product could seek approval through a regulatory route that does not exactly replicate ZYNRELEF. This may create competition without waiting for every ZYNRELEF patent to expire, depending on the product’s formulation and labeling.
What is the commercial outlook for ZYNRELEF?
ZYNRELEF has a favorable near-term growth profile if Heron continues to expand orthopedic and ambulatory surgery center penetration. The central commercial opportunity is conversion from generic local anesthetics in procedures where prolonged pain control and opioid reduction have measurable economic value.
The principal risks are:
- Slower-than-expected hospital formulary conversion.
- Pressure from Exparel and other long-acting anesthetics.
- Generic bupivacaine substitution.
- Reimbursement constraints.
- Limited surgeon willingness to change established protocols.
- Product concentration in Heron’s revenue base.
- Future Paragraph IV litigation.
- Manufacturing or supply interruption.
- Declining price realization as institutional purchasing scales.
The asset’s patent strength is meaningful but not absolute. Its strongest protection comes from the combination of formulation, extended-release delivery, and surgical-use claims. Its commercial durability will depend on whether Heron can make ZYNRELEF part of standard perioperative protocols rather than position it only as a premium analgesic.
Key Takeaways
- ZYNRELEF is Heron Therapeutics’ principal commercial product and primary revenue driver.
- Net product sales increased from approximately $89 million in 2022 to approximately $142 million in 2023 and approximately $169 million in 2024.
- The product competes with Exparel, generic bupivacaine, ropivacaine, regional anesthesia, and multimodal pain protocols.
- The FDA approved ZYNRELEF in 2021 and later expanded its surgical indications.
- Biosimilar risk does not apply because ZYNRELEF is a small-molecule combination product.
- Patent protection extends into the 2030s, with public records indicating certain rights through approximately 2037.
- Future Paragraph IV litigation is the principal near-term exclusivity risk.
- The strongest market opportunity is in orthopedic, abdominal, and ambulatory surgery procedures.
- Heron’s financial trajectory is improving, but revenue concentration makes ZYNRELEF adoption and patent durability critical to valuation.
FAQs
Does ZYNRELEF replace opioids after surgery?
No. ZYNRELEF is intended to reduce postsurgical pain and may reduce opioid requirements, but it does not eliminate the need for rescue analgesia in all patients.
Is ZYNRELEF covered by Medicare?
Coverage depends on the surgical setting, billing pathway, payer policy, and hospital purchasing arrangement. Payment treatment can differ between inpatient, outpatient, and ambulatory surgery center procedures.
Is ZYNRELEF more expensive than generic bupivacaine?
Yes. ZYNRELEF carries a branded-product premium over conventional generic bupivacaine. Its economic justification depends on reduced opioid use, improved recovery, or lower postoperative resource utilization.
Can a generic manufacturer copy the ZYNRELEF kit?
A competing manufacturer must satisfy FDA requirements and avoid or successfully challenge applicable formulation, delivery, method-of-use, and kit-related patent claims. A product with a different presentation may pursue a different regulatory pathway.
What would most increase ZYNRELEF sales?
The largest potential drivers are broader hospital formulary adoption, increased use in total joint replacement and ambulatory surgery, stronger evidence of hospital cost savings, and successful conversion from Exparel or generic local anesthetic protocols.
References
-
Heron Therapeutics, Inc. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
Heron Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2021-2023). ZYNRELEF prescribing information and supplemental approval materials. FDA.
-
U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 10,695,324. Patent Center.
-
U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 11,020,361. Patent Center.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.
